● Recruiting

A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy

Condition: Multiple System Atrophy - Parkinsonian Subtype (MSA-P) · Sponsor: iRegene Therapeutics Co., Ltd.

PhasePhase 1

Planned participants9

Who can joinAll sexes, 30 Years to 70 Years

Healthy volunteersNo

About this study

This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Multiple System Atrophy.

This description comes directly from the study's public registry record.

Talk to the study team

Meng Cai, Ph.D · 0086-027-59337986 · caimeng@iregene.com

Jing Zhao, PhD · zhaojing@iregene.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07289477